Salarius Pharmaceuticals Future Growth

Future criteria checks 0/6

Salarius Pharmaceuticals's earnings are forecast to decline at 56.1% per annum. EPS is expected to decline by 69.8% per annum.

Key information

-56.1%

Earnings growth rate

-69.8%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	09 Sep 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:FP10 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	N/A	-23	N/A	N/A	1
12/31/2024	N/A	-22	N/A	N/A	1
6/30/2024	N/A	-6	-8	-8	N/A
3/31/2024	N/A	-9	-11	-11	N/A
12/31/2023	N/A	-13	-13	-13	N/A
9/30/2023	N/A	-18	-16	-16	N/A
6/30/2023	N/A	-30	-18	-18	N/A
3/31/2023	N/A	-31	-17	-17	N/A
12/31/2022	N/A	-32	-19	-18	N/A
9/30/2022	N/A	-29	-17	-16	N/A
6/30/2022	N/A	-19	-13	-11	N/A
3/31/2022	1	-17	-12	-11	N/A
12/31/2021	2	-13	-10	-10	N/A
9/30/2021	3	-11	-9	-9	N/A
6/30/2021	5	-9	-10	-10	N/A
3/31/2021	5	-8	-9	-9	N/A
12/31/2020	5	-8	-10	-10	N/A
9/30/2020	5	-7	-12	-12	N/A
6/30/2020	4	-8	-14	-14	N/A
3/31/2020	4	-7	-13	-13	N/A
12/31/2019	3	-7	-12	-12	N/A
9/30/2019	3	-6	-9	-9	N/A
6/30/2019	3	-4	2	2	N/A
3/31/2019	2	-3	3	3	N/A
12/31/2018	2	-2	4	4	N/A
9/30/2018	1	-2	3	3	N/A
12/31/2017	2	-2	N/A	-1	N/A
12/31/2016	3	-1	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FP10 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FP10 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FP10 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if FP10's revenue is forecast to grow faster than the German market.

High Growth Revenue: FP10 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if FP10's Return on Equity is forecast to be high in 3 years time

Salarius Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Salarius Pharmaceuticals, Inc., Annual General Meeting, Dec 20, 2024

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting

New major risk - Shareholder dilution

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Receives Notice from Nasdaq Stock Market

Insufficient new directors

Salarius Pharmaceuticals, Inc. FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals, Inc. announced that it has received $6.000001 million in funding

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. to Present SP-3164 Targeted Protein Degrader Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. Announces Investigators Present Clinical Data on Its Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Reports Impairment of Goodwill for the Three Months Ended September 30, 2022

Salarius Pharmaceuticals Presents Favorable Preclinical Data on Sp-3164 At the 5Th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals, Inc. Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for Ongoing Trial of Seclidemstat as A Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Salarius Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Salarius Pharmaceuticals, Inc. (NasdaqCM:SLRX) acquired certain assets of DeuteRx, including DRX-164 for approximately $220 million.

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

Second quarter 2021 earnings released: US$0.069 loss per share (vs US$0.13 loss in 2Q 2020)

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’S Safety, Dosing, and Drug Activity At American Society of Clinical Oncology (Asco) 2021 Annual Meeting

Salarius Pharmaceuticals, Inc. Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

First quarter 2021 earnings released: US$0.061 loss per share (vs US$0.22 loss in 1Q 2020)

Full year 2020 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2019)

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Salarius Pharmaceuticals, Inc. Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

Salarius Pharmaceuticals, Inc. Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

New 90-day high: €1.16

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Salarius Pharmaceuticals, Inc. Announces Developing Seclidemstat

New 90-day high: €1.05

New 90-day high: €0.88

Third quarter 2020 earnings released: US$0.096 loss per share

Revenue beats expectations

New 90-day low: €0.66

New 90-day low: €0.67

New 90-day low - €0.79

New 90-day low - €0.83

Earnings released

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.353451 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies